U.S. drugmaker Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot targeting the BA.4/5 subvariants produced a strong antibody response in humans than the original shot after one month.

German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany’s BioNTech and pressed for Beijing to allow the shot to be made freely available to Chinese citizens.

Moderna Inc cut its annual sales forecast for its COVID-19 vaccine, citing short-term supply constraints that would push some deliveries to next year, sending its shares down nearly 11% before the bell.

Reports of heavy periods – bleeding characterized by increased volume and/or duration that interferes with the quality of life – have been observed during clinical trials, from cases in the real world and in medical literature, according to the European Medicines Agency.

Pfizer’s attempt to as much as quadruple its current U.S. prices for its COVID-19 vaccines going forward could spur revenues for years, analysts said.

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans.

Novavax Inc. said on Wednesday data from studies in adults and adolescents showed that the booster dose of its COVID vaccine produced robust antibodies against several Omicron variants, including BA.1, BA.2 and BA.5.

Indonesia is in talks with several African countries, including Nigeria, to export and donate its homemade COVID-19 vaccine, its developer said on Friday, after becoming the first country in Southeast Asia to approve a domestically developed COVID shot.

The Nasdaq-listed company and Australia’s Victoria state said they signed a partnership to create a centre, which would run clinical research of experimental messenger ribonucleic acid, or mRNA, vaccines and therapies with the aim of attracting experts from around the world.

Moderna Inc. has held talks with the Chinese government about supplying COVID-19 vaccines, but no decision has yet been made, CEO Stephane Bancel stated.